David Meek, Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)
February 16, 2022 06:49 AM ESTUpdated 10:59 AM
Bioregnum
FDA+

Mi­rati gets a stan­dard re­view for its 'break­through' KRAS drug. And that is caus­ing some hand wring­ing

Af­ter the mar­ket close on Mon­day, Mi­rati is­sued a state­ment that the FDA had ac­cept­ed its ap­pli­ca­tion for their KRAS drug ada­gra­sib and is giv­ing …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times